Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518

Mirjam Crul, Laurens V. Beerepoot, Ellen Stokvis, Johannes S.P. Vermaat, Hilde Rosing, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: To investigate the pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase (MMP) inhibitor ABT-518. Methods: Plasma and urine samples were obtained from six patients included in a phase I trial in which ABT-518 was given once daily via the oral route. Samples were analyzed by LC-MS/MS, ELISA and immunocapture assay. The pharmacokinetics of the parent compound and of detectable metabolites were calculated. Results: After a single dose of ABT-518 peak plasma levels were reached within 4-8 h. ABT-518 had an estimated clearance (Cl/F) of approximately 3 l/h, an estimated volume of distribution (V/F) of over 70 l and a terminal half-life (T1/2) of 20 h. At least six different metabolites were formed. Pharmacodynamic analysis for angiogenic growth factors (bFGF and VEGF) showed plasma and urine levels in the picogram range and for total MMP-9 and MMP-2 or MMP-9 activity showed plasma and urine levels in the nanogram range. Conclusions: The MMP inhibitor ABT-518 is extensively metabolized in humans. No significant correlations between pharmacokinetics and pharmacodynamics could be established.

Original languageEnglish
Pages (from-to)473-478
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number6
DOIs
Publication statusPublished - 19 Dec 2002

Cite this